tiprankstipranks
GT Biopharma (GTBP)
NASDAQ:GTBP

GT Biopharma (GTBP) Technical Analysis

174 Followers

Technical Sentiment

Overall Consensus
Strong Sell
2Bullish
5Neutral
15Bearish
Technical Analysis Consensus
Sell
2Bullish
5Neutral
3Bearish
Moving Average Consensus
Strong Sell
0Bullish
0Neutral
12Bearish
GT Biopharma’s (GTBP) Moving Averages Convergence Divergence (MACD) indicator is >-0.01, suggesting GT Biopharma is a Buy.
GT Biopharma’s (GTBP) 20-Day exponential moving average is 0.24, while GT Biopharma’s (GTBP) share price is $0.215, making it a Sell.
GT Biopharma’s (GTBP) 50-Day exponential moving average is 0.25, while GT Biopharma’s (GTBP) share price is $0.215, making it a Sell.

GT Biopharma (GTBP) Pivot Points

Nov 29, 2023, 11:11 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
0.16
0.19
0.20
0.23
0.25
0.28
0.29
Fibonacci
0.19
0.20
0.21
0.23
0.25
0.26
0.28
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

GT Biopharma (GTBP) Moving Averages

Nov 29, 2023, 11:11 AM
Period
Simple
Exponential
MA5
0.23Sell
0.23Sell
MA10
0.23Sell
0.23Sell
MA20
0.24Sell
0.24Sell
MA50
0.25Sell
0.25Sell
MA100
0.26Sell
0.29Sell
MA200
0.35Sell
0.44Sell
GT Biopharma’s (GTBP) 10-Day exponential moving average is 0.23, while GT Biopharma’s (GTBP) share price is $0.215, making it a Sell.
GT Biopharma’s (GTBP) 100-Day exponential moving average is 0.29, while GT Biopharma’s (GTBP) share price is $0.215, making it a Sell.
GT Biopharma’s (GTBP) stock price is $0.215 and GT Biopharma’s (GTBP) 50-day simple moving average is 0.25, creating a Sell signal.
GT Biopharma’s (GTBP) stock price is $0.215 and GT Biopharma’s (GTBP) 100-day simple moving average is 0.26, creating a Sell signal.
GT Biopharma’s (GTBP) stock price is $0.215 and GT Biopharma’s (GTBP) 200-day simple moving average is 0.35, creating a Sell signal.

GT Biopharma (GTBP) Technical Indicators

Nov 29, 2023, 11:11 AM
Name
Value
Implied Action
RSI (14)
40.82
Neutral
STOCH (9,6)
44.70
Neutral
STOCHRSI (14)
21.17
Neutral
MACD (12,26)
>0.01
Buy
ADX (14)
24.07
Neutral
Williams %R
82.14
Buy
CCI (14)
91.64
Neutral
ATR (14)
0.02
-
Ultimate Oscillator
29.48
Sell
ROC
18.52
Sell
GT Biopharma’s (GTBP) Relative Strength Index (RSI) is 40.82, creating a Neutral signal.
GT Biopharma’s (GTBP) Trend Strength Indicator (ADX) is 24.07, creating a Neutral signal.
GT Biopharma’s (GTBP) Commodity Channel Index (CCI) is -91.64, creating a Neutral signal.
GT Biopharma’s (GTBP) Price Rate of Change (ROC) is -18.52, creating a Sell signal.

FAQ

Is GTBP a Buy, Hold, or Sell?
Based on GTBP’s technical indicators, GTBP is a Strong Sell.
    What is GTBP’s RSI (14)?
    GTBP’s RSI (14) is 40.82, which suggests GTBP is a Neutral.
      What is GTBP’s MACD?
      GTBP’s MACD is >-0.01, which suggests GTBP is a Buy.
        What is GTBP’s 5-day moving average?
        GTBP’s 5-day moving average is 0.23, which suggests GTBP is a Sell.
          What is GTBP’s 20-day moving average?
          GTBP 20-day moving average is 0.24, which suggests GTBP is a Sell.
            What is GTBP’s 50-day moving average?
            GTBP’s 50-day moving average is 0.25, which suggests GTBP is a Sell.
              What is GTBP’s 200-day moving average?
              GTBP’s 200-day moving average is 0.35, which suggests GTBP is a Sell.
                What is GTBP’s Williams % R (14)?
                GTBP’s Williams % R (14) is -82.14, which suggests GTBP is a Buy.
                  What is GTBP’s CCI (14)?
                  GTBP’s CCI (14) is -91.64, which suggests GTBP is a Neutral.

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis